BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24879338)

  • 1. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
    Seo AN; Kwak Y; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
    PLoS One; 2014; 9(5):e98528. PubMed ID: 24879338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
    Varga Z; Tubbs RR; Moch H
    PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
    Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
    Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
    Pala EE; Bayol U; Ozguzer A; Akman O
    Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
    Unal B; Karaveli FS; Pestereli HE; Erdogan G
    Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions.
    Moussa M; Badawy A; Helal N; Hegab F; Youssef M; Aboushousha T; Al Faruok L; Elwy D
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2357-2366. PubMed ID: 32856866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH).
    Thang VH; Tani E; Van TT; Krawiec K; Skoog L
    Acta Oncol; 2011 Apr; 50(3):360-6. PubMed ID: 21338271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
    Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL
    Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole - tissue sections.
    Kılıçarslan A; Dogan HT; Süngü N; Dogan M; Yalcin A; Dede DŞ
    Pol J Pathol; 2018; 69(2):143-149. PubMed ID: 30351861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
    Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
    Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Wang B; Guo L; Liu X; Wang B; Ying J; Xue L; Lu N
    Diagn Pathol; 2020 Mar; 15(1):27. PubMed ID: 32209107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
    Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
    BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
    Boers JE; Meeuwissen H; Methorst N
    Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
    Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
    J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.